

Supplementary table 3: Characteristics of CSU patients under omalizumab treatment

Phenotype of CSU patients	N=33 patients under OZB treatment
Sex	77.7% female (n=26)
Associated autoimmune disease	17.3%
Associated angioedema	30.3%
Associated thyroid Antibodies	16%
Positive skin prick test to inhalants	52.6%
Positive IgE anisakis	18.2%
UAS 7 questionnaire	UAS 7 before omalizumab: 30.1 UAS 7 after omalizumab: 5
Treatment with omalizumab	Complete treatment: 79% (n=26) Incomplete treatment: 21% (n=7)